OncoMed Pharmaceuticals, Inc.
     
 
 

Press Releases

All Releases
View Summary OncoMed Announces Workforce Reduction
Apr 24, 2017
PDF 17.4 KB Add to Briefcase
View Summary OncoMed's Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Apr 17, 2017
PDF 17.8 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
Apr 10, 2017
PDF 14.5 KB Add to Briefcase
View Summary OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint
Apr 10, 2017
PDF 22.3 KB Add to Briefcase
View Summary OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017
Apr 5, 2017
PDF 19.4 KB Add to Briefcase
View Summary OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
Apr 3, 2017
PDF 19.4 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
Mar 8, 2017
PDF 34.0 KB Add to Briefcase
View Summary OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
Mar 2, 2017
PDF 14.7 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Report Fourth Quarter and Year End Financial Results on March 8, 2017
Mar 1, 2017
PDF 12.0 KB Add to Briefcase
View Summary OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
Feb 13, 2017
PDF 16.1 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences
Feb 8, 2017
PDF 13.3 KB Add to Briefcase
View Summary OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients
Jan 20, 2017
PDF 14.8 KB Add to Briefcase
View Summary OncoMed Announces Year-End Cash Balance and 2017 Outlook
Jan 5, 2017
PDF 23.3 KB Add to Briefcase
View Summary OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
Jan 4, 2017
PDF 16.1 KB Add to Briefcase
View Summary OncoMed Announces Departure of Chief Medical Officer
Dec 5, 2016
PDF 14.4 KB Add to Briefcase
View Summary OncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 29, 2016
PDF 63.8 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
Nov 22, 2016
PDF 11.0 KB Add to Briefcase
View Summary OncoMed to Present Clinical Data for Anti-RSPO3 and Anti-DLL4/VEGF Bispecific Antibody at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 15, 2016
PDF 14.3 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
Nov 1, 2016
PDF 27.4 KB Add to Briefcase
View Summary OncoMed Pharmaceuticals to Report Financial Results for the Third Quarter on Tuesday, November 1, 2016
Oct 26, 2016
PDF 12.2 KB Add to Briefcase
Showing 1-20 of 202 Page: 1 2 3 4 5 ... 11  Next 20
Add to Briefcase = add release to Briefcase
Stock Quote (NASDAQ: OMED)
Price:
3.94
Change:
- 0.06
Day High:
4.05
Day Low:
3.87
Volume:
259,157
4:00 PM ET on Apr 28, 2017
Delayed at least 20 minutes.
Provided by eSignal.
Search Investor Relations